GangaGen, Inc. is a biotechnology company focused on the development of proprietary products for the prevention and treatment of bacterial infections, particularly infections that are resistant to antibiotics, through the application of contemporary molecular and clinical sciences. The Company's technology has arisen from its studies of bacteriophage, nature’s antibiotics.
GangaGen's unique business strategy is to maximize efficiency through cost-effective R & D operations in Bangalore, India, pursuing the treatment of commercially significant infections that require the most straightforward and least expensive clinical trials.
GangaGen Inc. was initially formed September 23, 2000 by CEO and founder Dr. J. Ramachandran in Bangalore, India, as GangaGen Biotechnologies Pvt Ltd (GBPL) to develop novel therapies for treating antibiotic-resistant infection. Based on the emerging opportunities for treating bacterial infection in the medical, veterinary, agricultural and environmental settings globally, and the interest of investors in the U.S. and Canada, GangaGen Inc was incorporated as a Delaware Corporation in August 2001.
GangaGen Inc. received permission from the Ministry of Commerce & Industry, Govt. of India on December 21, 2001 to convert GBPL into a fully owned subsidiary of GangaGen Inc.
The long-term objective of the Company is to commercially develop products to control multiple species of bacteria pathogenic to humans, particularly antibiotic-resistant strains, based on its knowledge of bacteriophage. GangaGen's business strategy is to pursue specific human, initially topical, applications where there is an opportunity to shorten the long product development timeline by focusing on those indications that require shorter clinical trials and enable faster regulatory approval.
The company’s lead product is a recombinant protein, P128, that binds to and kills Staphylococcus, including methicillin-resistant strains of S.aureus (MRSA). This product is in late preclinical development.
The second human topical application the Company is pursuing is the control of Pseudomonas aeruginosa in burns & wounds. The product is also expected to be valuable in treating P.aeruginosa infections in the lungs of patients with cystic fibrosis. The Company intends to pursue these with strategic partners.